몰컬린 바이오테크MBRX 주가

Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting

The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical trials evaluating

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject...

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

[10-Q] 분기 실적 — FORM 10-Q

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rates in relapsed AML patients.

Moleculin Biotech Inc - to unblind Miracle trial data before June 30, 2026 - SEC filing

Moleculin Biotech Inc: Moleculin Biotech Inc - to unblind Miracle trial data before June 30, 2026 - SEC filing Moleculin Biotech Inc - Miracle trial on track to complete part A recruitment in Q3...